{"id":250898,"date":"2025-08-08T00:00:00","date_gmt":"2025-08-08T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidim0081-biopharma-idiopathic-pulmonary-fibrosis-epidemiology-3\/"},"modified":"2026-03-31T10:25:26","modified_gmt":"2026-03-31T10:25:26","slug":"epidim0081-biopharma-idiopathic-pulmonary-fibrosis-epidemiology-europe","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0081-biopharma-idiopathic-pulmonary-fibrosis-epidemiology-europe\/","title":{"rendered":"Idiopathic Pulmonary Fibrosis &#8211; Epidemiology &#8211; Europe"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of idiopathic pulmonary fibrosis (<abbr data-abbreviation-entity=\"5913\" title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of <abbr data-abbreviation-entity=\"5913\" title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan, and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr data-abbreviation-entity=\"5913\" title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people diagnosed with <abbr data-abbreviation-entity=\"5913\" title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr>, how many in each country across the developed world are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr data-abbreviation-entity=\"5913\" title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr data-abbreviation-entity=\"10739\" title=\"Microsoft\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 11 <abbr data-abbreviation-entity=\"5913\" title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incident cases of <abbr title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of stage 1 <abbr title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of stage 2 <abbr title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of stage 3 <abbr title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of <abbr data-abbreviation-entity=\"5913\" title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr> with gastroesophageal reflux disease<\/li>\n<li>Diagnosed prevalent cases of <abbr data-abbreviation-entity=\"5913\" title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr> with emphysema.<\/li>\n<li>Diagnosed prevalent cases of <abbr data-abbreviation-entity=\"5913\" title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr> with pulmonary hypertension.<\/li>\n<li>Diagnosed prevalent cases of <abbr data-abbreviation-entity=\"5913\" title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr> with obstructive sleep apnea.<\/li>\n<li>Diagnosed prevalent cases of drug-treated <abbr title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr>.<\/li>\n<li>Diagnosed\u00a0prevalent cases of non-drug-treated <abbr title=\"idiopathic pulmonary fibrosis\">IPF<\/abbr>.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-250898","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-idiopathic-pulmonary-fibrosis","biopharma-therapy-areas-respiratory","biopharma-product-epidemiology","biopharma-geography-europe","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250898","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250898\/revisions"}],"predecessor-version":[{"id":575749,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250898\/revisions\/575749"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250898"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}